Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Summit Therapeutics Inc (SMMT) vs Teradyne, Inc. (TER) Price & Performance

Summit Therapeutics IncTrade
Teradyne, Inc.Trade

Price performance (Past 24H)

Key statistics

Summit Therapeutics Inc vs Teradyne, Inc. — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Teradyne, Inc. trades at $403.49 (market cap $59.34B). The key difference: Teradyne, Inc. is far larger — about 4.9× Summit Therapeutics Inc's market cap, and Teradyne, Inc. pays a 0.14% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

SMMTTER
Market Cap
$12.06B$59.34B
Sector
HealthTechnology
52-Week High
$26.98$483.84
52-Week Low
$12.55$109.30
Enterprise Value
$11.39B$59.09B
Dividend Yield
0.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.

Teradyne, Inc.

Teradyne (TER) is trading at $402.65, up 10.28% with strong bullish momentum following better-than-expected Q2 2026 earnings. The stock shows robust fundamentals with record revenue of $1.3 billion in Q2, net income margin of 25.77%, and consistent earnings beats. Technical indicators suggest bullish momentum with the current price near resistance at $400, while analyst consensus remains strongly positive with a $481.63 price target.

Outlook remains positive driven by AI-led semiconductor test demand and robotics growth, though elevated valuation multiples (P/E 52.14) and market volatility present risks. The company's strong guidance and institutional support suggest continued upside potential, but investors should monitor competitive pressures in the semiconductor equipment sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT

About Teradyne, Inc.

Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.

Read more on TER